Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > Why Alison?

<< Previous

Bullboard Posts

Next >>

Comment by RJSullivanon Jul 10, 2017 5:17pm

125 Views

Post# 26452719

RE:RE:Why Alison?

Alison clearly has very little understanding of how the capital markets and investor relations work. Look at the market cap before she was made president and how it continued downward month after month before being destroyed by the share consolidation.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market